FindMyKOL

Joan Duggan, MD

Basic profile

University of Toledo Medical Center

ORCIDOn fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionToledo, OH · MidwestSpecialtyInfectious DiseaseFocusInfectious Disease
Active KOLFindMyKOL type: RegionalLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Joan Duggan is an Infectious Disease physician affiliated with University of Toledo Medical Center. OpenAlex indexes 94 publications with 1,163 citations (h-index 17).

Overview

Scholarship

indexed output and impact (OpenAlex)
94publications

Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.

1,163citations

Citations across these publications.

17h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
3companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Industry payments

3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • Theratechnologies Inc.
    Program year20251 payment
    $39
  • GSK
    Program year20243 paymentsResearch
    $15,125
  • ViiV Healthcare
    Program year20234 paymentsResearch
    $8,483
All 8 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Anti-infectives

    47.7%
    Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor17.2%
    Tivicay64%Dovato21%Juluca15%
    Part D<11 patients
    Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor14.8%
    Descovy92%Triumeq9%
    Part D<11 patients

    + 7 more classes in this area

  • Cardiovascular

    30.9%
    Statin12.5%
    Atorvastatin Calcium100%
    Part D≥23 patients
    Calcium channel blocker6.2%
    Amlodipine Besylate100%
    Part D<11 patients

    + 4 more classes in this area

  • Metabolism & gastrointestinal

    8.4%
    Proton pump inhibitor6.9%
    Pantoprazole Sodium45%Omeprazole35%Esomeprazole Magnesium20%
    Part D<11 patients
    Biguanide (metformin)1.5%
    Metformin Hcl100%
    Part D<11 patients
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”